Core Viewpoint - The report highlights the performance and investment strategy of the Great Wall Healthcare Mixed Securities Investment Fund for the second quarter of 2025, emphasizing its focus on the healthcare industry and the fund's net value growth during the period [1][10]. Fund Overview - Fund Name: Great Wall Healthcare Mixed Fund - Fund Code: 000339 - Fund Type: Contractual open-end fund - Total Fund Shares at Period End: 117,458,484.44 shares - Investment Objective: Focus on listed companies in the healthcare industry, aiming for performance that exceeds the benchmark while controlling risks [1][2]. Investment Strategy - The fund employs a mixed investment strategy, adjusting asset allocation based on market conditions. It combines top-down and bottom-up approaches to analyze macroeconomic factors and the fundamentals of investable stocks [2][3]. - The healthcare sector includes various sub-industries such as pharmaceuticals, traditional Chinese medicine, biological products, medical services, and medical devices. The fund selects outstanding companies from these sub-industries for its stock portfolio [2][3]. Performance Benchmark - The performance benchmark is composed of 90% of the CSI Pharmaceutical and Health Index return and 10% of the China Bond Composite Wealth Index return [3]. Risk and Return Characteristics - The fund is characterized by a long-term average risk and expected return that is lower than equity funds but higher than bond and money market funds, categorizing it as a high-risk, high-return product [3]. Financial Performance - The net value growth rate of the Great Wall Healthcare Mixed Fund A for the past three months was 17.49%, while the benchmark return was 1.41% [10]. - Over the past six months, the fund's growth rate was 2.23%, compared to a benchmark return of 32.19% [10]. - The fund's performance over the past year showed a net value growth rate of 35.19%, with a benchmark return of 10.13% [10]. Investment Composition - As of the report period, the fund's total assets included approximately 265,126,026.09 yuan in stocks, accounting for 71.42% of the total fund assets [11]. - The fund's investment strategy mandates that at least 80% of its non-cash assets be invested in stocks of listed companies in the healthcare sector [6]. Fund Management - The fund manager, Great Wall Fund Management Co., Ltd., has adhered to relevant laws and regulations, ensuring the fair treatment of different investors and maintaining a disciplined investment approach [7][9].

据了解，长城医疗保健混合A成立于2014年2月，基金规模3.13亿元，成立来累计收益率161.82%。从持 有人结构来看，截至2024年末，长城医疗保健混合A的基金机构持有0.10亿份，占总份额的7.07%，个 人投资者持有1.28亿份，占总份额的92.93%。 4月17日，长城医疗保健混合A（000339）下跌0.29%，最新净值2.62元，连续3个交易日下跌，区间累 计跌幅2.02%。 截止2024年12月31日，长城医疗保健混合A前十持仓占比合计45.25%，分别为：美好医疗（7.57%）、 华海药业（6.42%）、泽璟制药-U（5.83%）、诺泰生物（5.11%）、恒瑞医药（4.29%）、新诺威 （3.82%）、联影医疗（3.36%）、爱博医疗（3.05%）、药明康德（2.93%）、普瑞眼科（2.87%）。 来源：金融界 公开信息显示，现任基金经理谭小兵女士:暨南大学会计学硕士。曾就职于联邦制药(成都)有限公司 (2004年7月至2005年7月)、东莞证券有限责任公司(2008年2月至2010年10月)、信达澳银基金管理有限公 司(2010年10月至2014年2月)。2014年2月加入长城基金管理有限 ...